

Anosmia

[View the current Anosmia InDepth page on BioPortfolio.com](#) ([PDF](#))

(<http://www.bioportfolio.com/indepth/Anosmia.html>) - Regularly Updated.

Anosmia is the lack of olfaction, or a loss of the ability to smell. It can be either temporary or permanent. A related term, hyposmia, refers to a decrease in the ability to smell, while hyperosmia refers to an increased ability to smell. Some people may be anosmic for one particular odor. This is called "specific anosmia" and may be genetically based. While termed as a disability, anosmia is often viewed in the medical field as a trivial problem. This is not always the case—esthesioneuroblastoma is a very rare cancerous tumor originating in or near the olfactory nerve. ([From the Wikipedia article Anosmia](#).)

Recent Publications on Anosmia:



- [Recovery of olfactory function after nine years of post-traumatic anosmia: a case report.](#)
INTRODUCTION: Olfactory loss due to head trauma is a common condition... 18th November, 2009
- J Med Case Reports. 2009 Sep 16;3:9283. ([DOI Direct Link](#))
- [\[Case of anosmia which appeared after anaphylactic shock due to intravenous heparin\]](#)
A patient developed anaphylactic shock after a heparin dosage during an... 18th November, 2009
Department of Anesthesiology, Tokyo Medical and Dental University, School- Masui. 2009 Aug;58(8):997-9.
- [Olfactory dysfunction affects thresholds to trigeminal chemosensory sensations.](#)
Next to olfaction and gustation, the trigeminal system represents a third... 11th November, 2009
CHU Ste.-Justine, Universite de Montreal, Montreal, QC, Canada; CERNEC,- Neurosci Lett. 2009 Nov 10. ([DOI Direct Link](#))
- [Olfactory dysfunction in Parkinsonism caused by PINK1 mutations.](#)
Hyposmia is a common nonmotor feature of Parkinson's disease (PD) and has... 6th November, 2009
CSS-Mendel Institute, Casa Sollievo della Sofferenza Hospital, Rome,- Mov Disord. 2009 Nov 4. ([DOI Direct Link](#))
- [Anosmia after general anaesthesia: a case report.](#)
Summary Although anaesthetic drugs are included among the aetiological... 24th October, 2009
Specialist, Academic Otorhinolaryngology Department, Papageorgiou- Anaesthesia. 2009 Oct 22. ([DOI Direct Link](#))
- [Sinonasal schwannoma of the middle turbinate.](#)
Paranasal schwannomas are uncommon lesions, representing less than 4% of... 13th October, 2009
Departments of Radiology, Baskent University School of Medicine, Ankara,- Diagn Interv Radiol. 2009 Oct 9. doi: 10.4261/1305-3825.DIR.1710-08.1. ([DOI Direct Link](#))
- [Olfactory dysfunction following herpetic meningoencephalitis.](#)
Herpetic meningoencephalitis (HME) is a rare but often lethal herpes... 13th October, 2009
Department of Otorhinolaryngology, Smell and Taste Clinic, University of- J Neurol. 2009 Oct 10. ([DOI Direct Link](#))

- [Study of smell and reproductive organs in a mouse model for CHARGE syndrome.](#)
*CHARGE syndrome is a multiple congenital anomaly syndrome characterised by...*8th October, 2009
Department of Genetics, University Medical Centre Groningen, University of- Eur J Hum Genet. 2009 Oct 7. ([DOI Direct Link](#))
- [Olfactory Performance Before and After Lung Transplantation: Quantitative Assessment and Impact on Quality of Life.](#)
*BACKGROUND: Although olfactory function significantly impacts quality of...*29th September, 2009
Clinic of Pulmonary Medicine, University Hospital Zurich, Zurich,- J Heart Lung Transplant. 2009 Sep 25. ([DOI Direct Link](#))
- [Bilateral limbic system destruction in man.](#)
*We report here a case study of a rare neurological patient with bilateral...*19th September, 2009
Department of Neurology, Division of Cognitive Neuroscience, University of- J Clin Exp Neuropsychol. 2009 Sep 17:1-19. ([DOI Direct Link](#))
- [Retronasal olfactory function in Parkinson's disease.](#)
*OBJECTIVES/HYPOTHESIS: Orthonasal olfaction is severely altered in PD...*16th September, 2009
Department of Otolaryngology-Head and Neck Surgery, University of Geneva- Laryngoscope. 2009 Nov;119(11):2280-3. ([DOI Direct Link](#))
- [PACS-1 mediates phosphorylation-dependent ciliary trafficking of the cyclic-nucleotide-gated channel in olfactory sensory neurons.](#)
*Impaired ciliary protein transport in olfactory sensory neurons (OSNs)...*11th September, 2009
Department of Pharmacology, University of Michigan, Ann Arbor, Michigan- J Neurosci. 2009 Aug 26;29(34):10541-51. ([DOI Direct Link](#))
- [The recent genetics of hypogonadotrophic hypogonadism - novel insights and new questions.](#)
*SUMMARY The complex organisation and regulation of the human...*2nd September, 2009
- Clin Endocrinol (Oxf). 2009 Aug 29. ([DOI Direct Link](#))
- [The genetic and molecular basis of idiopathic hypogonadotropic hypogonadism.](#)
*Idiopathic hypogonadotropic hypogonadism (IHH) has an incidence of 1-10...*27th August, 2009
Department of Molecular and Cellular Pharmacology, Leonard M. Miller- Nat Rev Endocrinol. 2009 Oct;5(10):569-76. Epub 2009 Aug 25. ([DOI Direct Link](#))
- [Smell disorders: a study of 132 patients from the first Smell and Taste Clinic of Thailand.](#)
*OBJECTIVE: To investigate types and possible causes of smell disorders in...*22nd August, 2009
Department of Otorhinolaryngology, Faculty of Medicine Siriraj Hospital,- J Med Assoc Thai. 2009 Aug;92(8):1057-62.

BioNews Results for Anosmia

- [Anosmia after general anaesthesia: a case report](#)
MDLinx: Nov 16 2009 1:41PM Matching: anosmia
- [Study Examines Treatment for Olfactory Loss After Viral Infection](#)
PSL Group: Oct 20 2009 6:13AM Matching: anosmia
- ["Stuffy Nose Mouse": A Promise to Help Treat 31 Million with Sinusitis](#)
Johns Hopkins Medicine: Oct 16 2009 8:19PM Matching: anosmia
- ["Stuffy Nose Mouse": A Promise to Help Treat 31 Million with Sinusitis](#)
Johns Hopkins Medicine: Oct 16 2009 8:19PM Matching: anosmia

Anosmia Clinical Trials:



- [Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders](#)

Anosmia Patents:



- 6677354- [Piperdines for use as orexin receptor antagonists](#)
- 7078565- [Benzamide derivatives as antagonists of orexin receptors](#)
- 7084126- [Methods and compositions for enhancing cellular function through protection of tissue components](#)
- 7101962- [Antibodies of the P2Y10 receptor useful in altering T lymphocyte function](#)
- 7108872- [Use of odorants to alter blood flow to the vagina, and article of manufacture thereof](#)
- 7166608- [N-aryl piperazine derivatives as orexin receptor antagonists](#)
- 7183293- [Ether derivatives useful as inhibitors of PDE4 isozymes](#)
- 7189757- [Treatment of sleep disorders using CNS target modulators](#)
- 7192950- [Benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists](#)
- 7211258- [Protein A compositions and methods of use](#)
- 7226791- [Polynucleotides encoding novel guanylate binding proteins \(GBP's\)](#)
- 7067519- [7,8,9,10-tetrahydro-6H-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2H-pyrrolo\[2,1-b\]-quinazolinone derivatives](#)
- 7067162- [Use of odorants to alter blood flow to the vagina](#)
- 7052857- [Expression of functional human olfactory cyclic nucleotide gated \(CNG\) channel in recombinant host cells and use thereof in cell based assays to identify GPCR modulators](#)
- 6699879- [Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists](#)
- 6703392- [1,2,3,4-tetrahydroisoquinoline derivatives](#)
- 6740655- [Pyrimidine carboxamides useful as inhibitors of PDE4 isozymes](#)
- 6770743- [Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuronal and neural injury](#)
- 6828333- [Ether derivatives useful as inhibitors of PDE4 isozymes](#)
- 6869945- [Pyrrolyl-and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes](#)
- 6894041- [Oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes](#)
- 6943160- [Morpholine derivatives as antagonists of orexin receptors](#)
- 6953810- [Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes](#)
- 6991785- [Method for administering a cytokine to the central nervous system and the lymphatic system](#)
- 7250518- [Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes](#)
- 7256170- [Spiro compounds as perfuming ingredients](#)
- 7432270- [N-aryl cyclic amines](#)
- 7435815- [Sulfonylamino-acetic acid derivatives](#)

- 7439346- [Nucleic acids arrays and methods of use therefor](#)
- 7452867- [Use of ADNF polypeptides for treating peripheral neurotoxicity](#)
- 7468367- [Ethylene diamine derivatives and their use as orexin-receptor antagonists](#)
- 7470710- [N-aryl cyclic amine derivatives as orexin receptor antagonists](#)
- 7507810- [Compositions and their uses directed to IL-4R alpha](#)
- 7538109- [Quinoxalin-3-one derivatives as orexin receptor antagonists](#)
- 7585968- [Compositions and their uses directed to thymus and activation-regulated chemokine \(TARC\)](#)
- 7604992- [Generation of neural stem cells from undifferentiated human embryonic stem cells](#)
- 7432251- [Methods of treating neurological diseases by regulating migration of neuroblasts in the adult nervous system with tenascin-R](#)
- 7425445- [Modulators that promote cell surface expression of odorant receptors](#)
- 7425331- [Protein A methods of use](#)
- 7273618- [Method for administering agents to the central nervous system](#)
- 7279578- [Sulfonylamino-acetic acid derivatives](#)
- 7317026- [CNS target modulators](#)
- 7335470- [Compilations of nucleic acids and arrays and methods of using them](#)
- 7354941- [Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes](#)
- 7355042- [Treatment of CNS disorders using CNS target modulators](#)
- 7365077- [Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor](#)
- 7374878- [Receptor fingerprinting, sensory perception, and biosensors of chemical sensants](#)
- 7405217- [N-aryl piperazine derivatives as orexin receptor antagonists](#)
- 7423052- [Piperidine compounds for use as orexin receptor antagoinst](#)
- 7610118- [Dispensing of multiple volatile substances](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

